Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) EBITDA: 2010-2025

Historic EBITDA for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $2.0 million.

  • OptimizeRx's EBITDA rose 12394.3% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 12393.16%. This contributed to the annual value of -$13.6 million for FY2024, which is 4831.19% up from last year.
  • Latest data reveals that OptimizeRx reported EBITDA of $2.0 million as of Q3 2025, which was up 12394.3% from $3.2 million recorded in Q2 2025.
  • Over the past 5 years, OptimizeRx's EBITDA peaked at $3.6 million during Q4 2024, and registered a low of -$10.9 million during Q4 2023.
  • For the 5-year period, OptimizeRx's EBITDA averaged around -$2.6 million, with its median value being -$3.6 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 993702.28% in 2022, then skyrocketed by 18506.27% in 2025.
  • Over the past 5 years, OptimizeRx's EBITDA (Quarter) stood at $621080.0 in 2021, then crashed by 239.17% to -$864348.0 in 2022, then plummeted by 1161.41% to -$10.9 million in 2023, then skyrocketed by 133.33% to $3.6 million in 2024, then tumbled by 43.59% to $2.0 million in 2025.
  • Its EBITDA stands at $2.0 million for Q3 2025, versus $3.2 million for Q2 2025 and -$2.1 million for Q1 2025.